Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823201 | PMC |
| http://dx.doi.org/10.3109/17453670903035583 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[A case of type 2A juvenile hereditary hemochromatosis].
Zhonghua Xin Xue Guan Bing Za Zhi
January 2025
Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou215031, China.
Higher Incidence of Diabetes in Asymptomatic Healthy Fatty Liver Patients of Bangladesh: Prompt Intervention can Avert Complications.
Euroasian J Hepatogastroenterol
December 2024
Department of Hepatology, Sheikh Hasina Medical College Hospital, Tangail, Bangladesh.
Background: The strong association between type 2 diabetes mellitus (T2DM) and fatty liver is well known, and its nomenclature has even recently changed to metabolic dysfunction-associated steatotic liver disease (MASLD). Healthy MASLD patients are frequently overlooked and maltreated, especially in Bangladesh. In this present study, we tried to correlate T2DM burden in apparently healthy, incidentally diagnosed fatty liver patients on ultrasound.
View Article and Find Full Text PDFReal-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
J Hepatol
January 2025
Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917). Electronic address:
Background And Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for treatment of compensated chronic hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking.
Methods: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a European retrospective multicenter real-life study (SAVE-D). Patient characteristics before and during BLV treatment were collected.
The Effect of Prolonged Antenatal Intravenous Immunoglobulin Treatment in Preventing Gestational Alloimmune Liver Disease-A Case Series with Literature Review.
AJP Rep
January 2025
Department of Pediatric Hematology-Oncology, Cooper Medical School of Rowan University, Camden, New Jersey.
Gestational alloimmune liver disease (GALD) is characterized by maternal IgG-directed fetal hepatocyte damage and can lead to severe liver failure and fetal or infant death. Moreover, GALD is associated with a near 90% risk of recurrence in subsequent pregnancies. We present a case of a newborn patient delivered to a 32-year-old G2P1000 mother who received prolonged antenatal intravenous immunoglobulin (IVIG) treatment during the current pregnancy due to the neonatal death of the first child from GALD-related liver failure.
View Article and Find Full Text PDFFirst report of iron-overload myopathy due to secondary hemochromatosis in a dog.
J Vet Sci
December 2024
Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea.
Importance: Hemochromatosis is rare in domestic animals, and iron-induced myopathy has not been reported in veterinary medicine. This case is the first report of iron-overload myopathy owing to hemochromatosis in a dog.
Case Presentation: A 9-year-old spayed female Donggyeong dog presented with severe forelimb lameness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!